NephJC Shorts

Nephrology produces far more new studies each week than NephJC can realistically cover in its twice‑monthly full reviews. That’s why we’re introducing NephJC Short- quick, sharp summaries of notable papers that caught the editorial team’s attention. Suggestions welcome, and feedback too.

🩳Read more on the blog post describing this initiative.

Upcoming NephJC Shorts

DIalysis Symptom COntrol-Pruritus Outcome Trial (DISCO-POT): A Multicenter Randomized Blinded Placebo-Controlled Crossover Trial (Collister D et al, Kidney Med, 2026)
A randomized cross-over trial of pre-and post-filter hemodiafiltration modalities in children on maintenance dialysis - effects on solute removal and blood pressure (Agbas A et al, Kidney Int, 2026)
Randomized Controlled Trial Comparing Lactoferrin Plus Iron to Iron Alone for Iron Deficiency Anemia in CKD (Divyaveer S et al, CJASN, 2026)

Blog

Raising sodium: can tolvaptan rival 3% hypertonic saline?

Testing Tolvaptan versus 3% saline and the rate of rise of serum sodium in healthy volunteers.

ARISE FLUIDS: Early vasopressors or more fluids in early septic shock?

Once a patient with septic shock has received the first liter, what comes next? ARISE FLUIDS reshapes the ED shock strategy before 30 mL/kg: more fluid or earlier vasopressors?

Dietary nitrate supplementation in CKD pregnancy

First trial in pregnancy and CKD after 30 years - aiming to test feasibility of nitrate administration in pregnant women with CKD

Is this the end of the beta-blocker debate in hemodialysis?

Non-dialyzable beta-blockers showed lower MACE, but the study was observational and shaped by regional prescribing habits that may hide confounding factors.

NephJC Short: 24-Month Iptacopan eGFR Data in IgA Nephropathy

Iptacopan decreases proteinuria, now we get the 24-month eGFR data in patients with IgA Nephropathy.

Finerenone across the proteinuric CKD spectrum

Cristina Popa dissects the FIND-CKD extras: GN subgroup and INFINITY analysis

NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial)

Does Dual BAFF/APRIL Blockade with Telitacicept Reduce Proteinuria in Persistent Proteinuric IgA Nephropathy?

Can we predict who benefits from steroids in IgAN? The PRED-IgAN Study

A post hoc analysis from TESTINg tries to answer this question

NephJC Short: The map and the territory: what measured GFR teaches us about our estimates

Is measured GFR more accurate than eGFR for forecasting adverse outcomes?

NephJC Short: Bayesian leash: How a prior walked the Tigris across the finish line

Can polymyxin B hemadsorption truly shift the fate of septic shock, or is the outcome already written?

NephJC Short: Finerenone in Type I Diabetic CKD - Fine, but doesn’t reach the Finish Line? FINEONE

In type 1 diabetes is finerenone helpful to reduce proteinuria?

NephJC Short: The Push Trial

Water, water everywhere. Can a wink, a nudge and a push increase water intake to decrease kidney stone formation?

Dialysis delay at what cost? Protein restriction as a distraction in the age of GDMT

The NephJC shorts on cost-efficiency of low-protein diets and ketoanalogues as a distraction from CKD-relevant therapies in the 21st century… wait, only if the comparator wouldn’t be dialysis.